Tiffany Mahmood

• Amyndas v. Zealand Pharma US et al.: Tiffany is a senior team member representing Zealand Pharma US in trade secret, unfair competition, and breach of contract litigation in Massachusetts Federal Court. The dispute stems from early due diligence discussions between Amyndas and parent company, Zealand Pharma A/S for a potential collaboration in developing novel peptides to treat complement-mediated diseases. No collaboration was entered into and Amyndas filed suit after Zealand Pharma A/S developed its own novel peptides and entered into a collaboration with another party, co-defendant Alexion Pharmaceuticals. The claims against Zealand Pharma A/S were dismissed at the pleading stage through the enforcement of a forum selection clause, which the First Circuit affirmed. Tiffany has argued and won several discovery motions in the case, and taken and defended the depositions of all key fact and expert witnesses, including Zealand Pharma’s Chief Executive Officer and lead scientists. The matter is still ongoing in Massachusetts Federal Court against US subsidiary, Zealand Pharma US, as well as with litigation in Denmark. Tiffany is also responsible for coordinating the Danish litigation.
• HotSpot Therapeutics v. Nurix: Tiffany was a senior team member representing HotSpot Therapeutics in trade secret and breach of contract litigation in California Federal Court. The technology at issue related to DNA encoded libraries used for drug discovery of E3 ligases in immunotherapy treatment of cancer. Tiffany argued and won discovery motions and took and defended several depositions of key scientists at HotSpot. The matter was resolved with a mutually acceptable settlement.

• Ossifi-Mab LLC. v. Amgen: Tiffany is a senior member of the team representing Ossif-Mab LLC in patent litigation against Amgen in Massachusetts Federal Court. The case involves Amgen’s osteoporosis drug, Evenity. Tiffany successfully argued discovery motions and the Goodwin team secured favorable claim construction during the Markman stage. The matter is still ongoing.
• Sanofi v. Sandoz: Goodwin represented Sandoz in Delaware Federal Court in patent litigation regarding its generic version of a metastatic castration-resistant prostate cancer drug, cabazitaxel. The litigation was a second-generation case where Sanofi asserted a new set family patents to prevent generic entry into the market. Tiffany was a key member of the trial team and prepared and presented key technical witnesses at trial.
• Genentech v. Sandoz: Goodwin represented Sandoz in Delaware Federal Court in patent litigation regarding a generic version of Esbriet (Pirfenidone), a drug used to treat idiopathic pulmonary fibrosis. As a key member of the trial team, Tiffany helped prepare several key technical witnesses. The Goodwin team secured a win for Sandoz after trial.

Tiffany is also committed to pro bono work. As an immigrant herself, Tiffany has represented several asylum seekers, VAWA applicants and their families, as well as clients of various background seeking legal permanent residency in the United States. Tiffany has also assisted in representing clients seeking methadone-assisted treatment while incarcerated.